University of Alberta virologist awarded Nobel Prize

Michael Houghton wins Nobel Prize in Physiology or Medicine along with Harvey J. Alter and Charles M. Rice for the discovery of the hepatitis C virus (HCV).

Read story

micheal-houghton-hepc-video-1.jpg

U of A Nobel winner’s impact extends from personal to global

Michael Houghton’s colleagues and trainees describe the determination that led him to discover the hepatitis C virus and continue his quest for vaccines that will save millions of lives.

michael-houghton-lab-600.jpg

COVID-19 has ‘created a new paradigm for developing vaccines,’ says U of A Nobel winner

A vaccine against SARS-CoV-2 is essential—and thanks to scientific advances and global will, it will likely come faster than any previous vaccine, according to virologist Michael Houghton.

houghton-video-lab-shot-reaction-story-teaser.png

Michael Houghton reacts to receiving Nobel Prize

U of A virologist Michael Houghton explains the only thing that could best receiving a Nobel Prize.

200323-lks-lorne-tyrrell-teaser-550px.jpg

How the U of A's Li Ka Shing Institute of Virology is responding to the COVID-19 crisis

Institute was designed for rapid response to viral pandemic.

rapid_response_1600x1200.jpg

New Trail: Rapid Response

When COVID‑19 hit, the U of A, home to one of the world’s pre-eminent virology institutes, was ready.

120215-hep-banner.jpeg

Hep C vaccine breakthrough

Feb 15, 2012: A University of Alberta researcher and Canada Excellence Research Chair in Virology has made the discovery of a vaccine that will potentially help combat hepatitis C.


Background

In 1989, Michael Houghton discovered the virus now known as hepatitis C with his colleagues Qui-Lim Choo and George Kuo. Because of their discovery, new screening tests were developed for blood donations, and by 1992, the virus was virtually eliminated from blood supplies. By 1996, this screening led to an annual reduction in new hep C infections by more than 80 per cent.

The hepatitis C virus is very virulent. It can lead to cirrhosis, end-stage liver disease, and liver cancer for people who carry the virus. To prevent the spread of hepatitis C, the world urgently needs a vaccine. In 2012, Houghton and his team here at the University of Alberta developed a vaccine that is now in late pre-clinical stage testing. Based on the discovery of the virus, antiviral therapies have also been developed that will cure 95 per cent of carriers. This is the first chronic viral illness that can be cured.

Since the outbreak, Dr. Houghton is leading an effort to produce a COVID-19 vaccine. He was successful in creating a vaccine for SARS-CoV-1 in 2004; however, this vaccine was never needed as the original SARS disappeared.

Dr. Houghton was appointed a full professor in the Department of Medical Microbiology and Immunology in the U of A Faculty of Medicine & Dentistry on June 1, 2010. His lab is in the Li Ka Shing Institute of Virology, which was created in 2010 through a gift of $25 million from the Li Ka Shing (Canada) Foundation as well as a commitment of $52.5 million from the Government of Alberta.


Media Coverage From Around the World